During Dec 2019 While it began with China, the book corona-virus, SARS-CoV-2, has generated mayhem in an exceedingly small amount of time worldwide. the microdevices, had been explored to understand their better cell-adhesion and viability home efficiently. We also propose for the use of a basic, wise and cost-effective lung-on-chip platform to study the SARS-CoV-2 pathogenesis in humans, drug toxicity testing and provide insights into antigenCantibody interactions. This platform will enable us to study multiple phenomena at a micro-level generating more reliable data and a better understanding of the underlying mechanisms of SARS-CoV-2 contamination and pathogenesis. strong class=”kwd-title” Keywords: SARS-CoV-2, COVID-19, Organ-on-chip, Lung-on-chip, Microfluidics, 3D-cell culture platform, Cell-adhesion, Polymeric-semipermeable-membrane Introduction On March 11, 2020, the WHO declared COVID-19 a pandemic considering the global apocalyptic effects of this disease. Although the scourge of this pandemic did not spare any nation, the top ten among most severely affected countries includes USA, Brazil, Russia, United VD2-D3 Kingdom, Italy, Spain, India, Germany, France and Peru. As per the May 31, 2020 situation report of WHO, the total number of cases and deaths worldwide are 5,934,936 and 367,166, respectively. Presently, no drug or vaccine for this disease is usually available. However, many potential vaccine and drug candidates are in a variety of stages of scientific trials. Nevertheless, taking into consideration the extended procedures of typical drug breakthrough pipeline it could take substantial period before these medications reach the marketplace. The rate of which COVID-19 spread throughout the world has been alarming, and based on the initial information about the pathogenesis the GYPA only option was to administer existing drugs approved for other infectious diseases; however, their usage for COVID-19 has been controversial because of the associated side effects. As the pandemic continues to spread, some important questions are imminent. Firstly, can existing drugs be repurposed for effective treatment of COVID-19? If so, how their efficacy can be evaluated rapidly? Secondly, what alternative options may be employed to reduce the proper period of scientific studies by rapid medication assessment and approval? The current want is certainly a screening system that can offer reliable leads to less period. The organ-on-chip technology (OOC) is certainly one such choice. Although field is within its infancy still, it VD2-D3 has remarkable potential to revamp the traditional drug breakthrough pipeline. The OOC technology surfaced using the pioneering function by Huh et al. on the Wyss Institute on the Harvard School in 2013 (Huh et al. 2011) where they defined a fabrication process for organ-on-chip using polydimethylsiloxane (PDMS). Because the inception of the idea, enormous efforts have got gone into changing this proof-of-concept into real working gadgets which are being globally utilized by research workers with a number of the discovery outcomes (Zhu et al. 2010; Neuzil 2012). Several startups have already been create as spin-offs from several research institutions throughout the world with huge marketplace potential and significant revenue-earning. In India, nevertheless, this promising system is not harnessed. In today’s pandemic circumstance, this technology may end up being a valuable device for not merely for performing medication toxicity assessment but could also be used for analysing the SARS-CoV-2 pathogenesis in individual. OOCs certainly are a designed network of microfluidic stations designed for mimicking the tiniest physiological and biochemical useful units of varied organs. The chip proportions are in the number of the few centimetres with microchannels network in the number of micrometres. These OOCs offer significant advantages over the original 2D cell lifestyle (Fig.?1) in petri-plates like:?(we) closely mimicking the cells organic microenvironment or niche, (ii) minimal requirements of reagents, (iii) choices for versatile design to match experiment needs and (iv) high throughput efficiency. Open up in another screen Fig. 1 Comparative display of the 2D, and b 3D cell lifestyle platfroms Initially, the principal objective for developing the OOC was to expedite the traditional drug breakthrough pipeline (Wikswo 2014). In today’s medication advancement and breakthrough paradigm, it requires about 10?years for an individual drug to attain the market. About VD2-D3 90% of the drugs fail at numerous stages of clinical trial (Kola and Landis 2004). This culminates into severe loss in terms of money and time, and sometimes volunteers life. In addition, the present animal testing is deemed inhumane with organisations such as PETA protesting against it. There have also been.